EXHIBIT 4.11

 

FIRST AMENDMENT TO
SENIOR SECURED CONVERTIBLE NOTE

 

This First Amendment to Senior Secured Convertible Note (this “Amendment”) dated as of October 12, 2023 (the “Effective Date”) is entered into by and between Chromocell Therapeutics Corporation, a Delaware corporation (the “Company”), and the purchasers identified on the signature pages hereto (each, a “Purchaser” and together, the “Purchasers”).

 

RECITALS

 

A.           The Purchasers and the Company entered into that certain Securities Purchase Agreement dated as of April 17, 2023 (the “Original Agreement”), pursuant to which the Company agreed to sell and issue to each Purchaser, a senior secured convertible note (the “Original Note”), convertible into shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), in an aggregate principal amount of up to $540,000.

 

B.           Pursuant to the Original Agreement, the Company issued to the Purchasers the Original Notes in an aggregate principal amount of $393,807.99, on April 17, 2023.

 

C.           The Purchaser and the Company desire to amend the Original Note pursuant to and in accordance with the terms set forth herein.

 

D.           Capitalized terms not otherwise defined herein shall have the meanings set forth in the Original Note and Original Agreement.

 

AGREEMENT

 

NOW THEREFORE, in consideration of the foregoing, and the covenants and agreements herein contained, and for other good and valuable consideration, the mutual receipt and legal sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:

 

1.            Title. The title of the Original Notes is hereby deleted in its entirety and replaced by the following:

 

SENIOR SECURED CONVERTIBLE PROMISSORY NOTE DUE NOVEMBER 1, 2023

 

2.            Preamble. The preamble of the Original Notes of the Original Agreement is hereby amended as follows:

 

(a)           The first paragraph of the Original Notes is hereby deleted in its entirety and replaced by the following:

 

“THIS SENIOR SECURED CONVERTIBLE PROMISSORY NOTE is a duly authorized and validly issued Senior Secured Convertible Promissory Note of CHROMOCELL THERAPEUTICS CORPORATION, a Delaware corporation (the “Company”), designated as its Senior Secured Convertible Promissory Note due on or after November 1, 2023 (this “Note”). This Note is one of a series of convertible notes issued pursuant to the terms of the Purchase Agreement. Capitalized terms used and not otherwise defined herein shall have the meanings set forth for such terms in the Purchase Agreement.”

 

1 

 

 

(b)           The definition of the Maturity Date in second paragraph of the preamble is hereby replaced by the following:

 

“on or after November 1, 2023 (the “Maturity Date”)”

 

3.            Miscellaneous.

 

(a)           Waivers and Amendments. Any provision of this Amendment may be amended, waived or modified only upon the written consent of the Company and the Purchaser.

 

(b)           Entire Agreement. This Amendment together with the Original Note constitutes the entire agreement of the Company and the Purchaser with respect to the subject matter hereof and supersedes all prior agreements and undertakings, both written and oral, between the Company and Purchaser with respect to the subject matter hereof. Except as amended by this Amendment, the Original Note shall continue in full force and effect.

 

(c)           Counterparts. This Amendment may be executed in one or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same agreement. Facsimile copies of signed signature pages will be deemed binding originals.

 

[Remainder of page intentionally left blank; signature page follows.]

 

2 

 

 

IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed and delivered by their proper and duly authorized officers as of the date and year first written above.

 

  COMPANY:
     
  CHROMOCELL THERAPEUTICS CORPORATION,
a Delaware corporation
     
  By:  /s/ Francis Knuettel II
    Name: Francis Knuettel II
    Title: Interim CEO and CFO

 

Signature Page to First Amendment to Original Note

 

 

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered by their proper and duly authorized officers as of the date and year first written above.

 

  PURCHASER: AME Equities LLC
     
  By:  /s/ Ruth Friedman
  Name: Ruth Friedman
  Title: Manager

 

Signature Page to First Amendment to Original Note 

 

 

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered by their proper and duly authorized officers as of the date and year first written above.

 

  PURCHASER: Aperture Healthcare Ventures Ltd.
     
  By:  /s/ Avi Wachtsman
  Name: Avi Wachtsman
  Title:

 

Signature Page to First Amendment to Original Note

 

 

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered by their proper and duly authorized officers as of the date and year first written above.

 

  PURCHASER: Balmoral Financial Group LLC
     
  By:  /s/ Ezra Friedberg
  Name: Ezra Friedberg
  Title: General Partner

 

Signature Page to First Amendment to Original Note

 

 

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered by their proper and duly authorized officers as of the date and year first written above.

 

  PURCHASER: Boswell Prayer Ltd
     
  By:  /s/ Rochelle Gross
  Name: Rochelle Gross
  Title: Director

 

Signature Page to First Amendment to Original Note

 

 

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered by their proper and duly authorized officers as of the date and year first written above.

 

  PURCHASER: David Danovitch
     
  By:  /s/ David Danovitch
  Name: David Danovitch
  Title:

 

Signature Page to First Amendment to Original Note

 

 

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered by their proper and duly authorized officers as of the date and year first written above.

 

  PURCHASER: DB Investor Group LLC
     
  By:  /s/ David Bocchi
  Name: David Bocchi
  Title: Trustee

 

Signature Page to First Amendment to Original Note 

 

 

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered by their proper and duly authorized officers as of the date and year first written above.

 

  PURCHASER: MDB Merchants Park LLC
     
  By:  /s/ Michael Bodner
  Name: Michael Bodner
  Title: Manager

 

Signature Page to First Amendment to Original Note 

 

 

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered by their proper and duly authorized officers as of the date and year first written above.

 

  PURCHASER: Motif Pharmaceutical Ltd
     
  By:  /s/ Zachary Klein
  Name: Zachary Klein
  Title: Director

 

Signature Page to First Amendment to Original Note 

 

 

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered by their proper and duly authorized officers as of the date and year first written above.

 

  PURCHASER: Nobi Investments Limited
     
  By:  /s/ Ariel Belilo
  Name: Ariel Belilo
  Title: Director

 

Signature Page to First Amendment to Original Note

 

 

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered by their proper and duly authorized officers as of the date and year first written above.

 

  PURCHASER: John Riley
     
  By:  /s/ John Riley
  Name: John Riley
  Title:

 

Signature Page to First Amendment to Original Note

 

 

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered by their proper and duly authorized officers as of the date and year first written above.

 

  PURCHASER: Sargeant Capital
     
  By:  /s/ Dan Nir
  Name: Dan Nir
  Title: Managing Partner

 

Signature Page to First Amendment to Original Note